Co-Diagnostics, Inc. to Present at 16th Next Generation Dx Summit in Washington, D.C.
Co-Diagnostics, Inc. (CODX) announced its participation in the 16th Annual Next Generation Dx Summit in Washington, D.C. from August 19-21, 2024. The company will sponsor, present, and host a booth at this event, which focuses on diagnostic advancement and technology innovation.
CEO Dwight Egan will present on the company's upcoming PCR platform, currently under FDA review, in a luncheon presentation titled "Co-Dx PCR Platform: The Future of Accessible Diagnostics" on August 19 at 12:15 PM ET.
Attendees can visit Booth #26 to learn about the Co-Dx PCR testing platform and the Co-Dx Logix Smart® suite of clinical laboratory solutions, including Research Use Only (RUO) tests for mpox virus. The company's mpox test was featured in a study published in the Oxford Academic journal Open Forum Infectious Diseases in December 2023.
Co-Diagnostics, Inc. (CODX) ha annunciato la sua partecipazione al 16° Annual Next Generation Dx Summit a Washington, D.C. dal 19 al 21 agosto 2024. L'azienda sarà sponsor, presenterà e ospiterà uno stand a questo evento, focalizzato sui progressi diagnostici e sull'innovazione tecnologica.
Il CEO Dwight Egan presenterà la prossima piattaforma PCR dell'azienda, attualmente in fase di revisione da parte della FDA, in una presentazione durante il pranzo intitolata "Co-Dx PCR Platform: Il Futuro della Diagnostica Accessibile" il 19 agosto alle 12:15 PM ET.
I partecipanti possono visitare il Porto #26 per scoprire la piattaforma di test PCR di Co-Dx e la suite di soluzioni di laboratorio clinico Co-Dx Logix Smart®, comprese le prove per Uso di Ricerca (RUO) per il virus mpox. Il test mpox dell'azienda è stato presentato in uno studio pubblicato nella rivista Oxford Academic Open Forum Infectious Diseases nel dicembre 2023.
Co-Diagnostics, Inc. (CODX) anunció su participación en el 16° Annual Next Generation Dx Summit en Washington, D.C. del 19 al 21 de agosto de 2024. La empresa será patrocinadora, presentará y tendrá un stand en este evento, que se centra en el avance diagnóstico y la innovación tecnológica.
El CEO Dwight Egan presentará sobre la próxima plataforma PCR de la empresa, actualmente en revisión por la FDA, en una presentación durante el almuerzo titulada "Co-Dx PCR Platform: El Futuro de la Diagnóstica Accesible" el 19 de agosto a las 12:15 PM ET.
Los asistentes pueden visitar el Stand #26 para conocer la plataforma de pruebas PCR de Co-Dx y la suite de soluciones de laboratorio clínico Co-Dx Logix Smart®, incluidas las pruebas de Uso Solo de Investigación (RUO) para el virus mpox. La prueba de mpox de la empresa fue presentada en un estudio publicado en la revista Oxford Academic Open Forum Infectious Diseases en diciembre de 2023.
Co-Diagnostics, Inc. (CODX)는 2024년 8월 19일부터 21일 사이에 워싱턴 D.C.에서 열리는 제16회 차세대 진단 서밋에 참가한다고 발표했습니다. 이 회사는 본 행사에서 후원, 발표 및 부스를 주최하며, 진단 발전과 기술 혁신에 중점을 두고 있습니다.
CEO 드와이트 에건(Dwight Egan)은 현재 FDA 검토 중인 회사의 PCR 플랫폼에 대해 "Co-Dx PCR Platform: 접근 가능한 진단의 미래"라는 제목의 점심 발표에서 8월 19일 오후 12시 15분(ET)에 발표할 예정입니다.
참석자들은 부스 #26를 방문하여 Co-Dx PCR 테스트 플랫폼과 Co-Dx Logix Smart® 임상 실험실 솔루션 모음을 배우고, mpox 바이러스에 대한 연구 전용(RUO) 테스트를 포함한 제품들을 알아볼 수 있습니다. 회사의 mpox 테스트는 2023년 12월 옥스포드 학술지 Open Forum Infectious Diseases에 발표된 연구에서 소개되었습니다.
Co-Diagnostics, Inc. (CODX) a annoncé sa participation au 16ème Sommet Annuel Next Generation Dx à Washington, D.C. du 19 au 21 août 2024. L'entreprise sera sponsor, présentera et tiendra un stand lors de cet événement axé sur l'avancement diagnostique et l'innovation technologique.
Le PDG Dwight Egan présentera la plateforme PCR à venir de l'entreprise, actuellement en cours d'examen par la FDA, lors d'une présentation pendant le déjeuner intitulée "Co-Dx PCR Platform: L'Avenir de la Diagnostique Accessible" le 19 août à 12h15 (ET).
Les participants peuvent visiter le Stand #26 pour en apprendre davantage sur la plateforme de test PCR de Co-Dx et la suite de solutions de laboratoire clinique Co-Dx Logix Smart®, y compris les tests à usage de recherche (RUO) pour le virus mpox. Le test mpox de la société a été présenté dans une étude publiée dans le journal Oxford Academic Open Forum Infectious Diseases en décembre 2023.
Co-Diagnostics, Inc. (CODX) gab seine Teilnahme am 16. jährlichen Next Generation Dx Summit in Washington, D.C. vom 19. bis 21. August 2024 bekannt. Das Unternehmen wird diesen Event sponsern, präsentieren und einen Stand betreiben, der sich auf diagnostische Fortschritte und technologische Innovationen konzentriert.
CEO Dwight Egan wird über die bevorstehende PCR-Plattform des Unternehmens, die sich derzeit in Überprüfung durch die FDA befindet, in einer Mittagspräsentation mit dem Titel "Co-Dx PCR Platform: Die Zukunft der zugänglichen Diagnostik" am 19. August um 12:15 Uhr ET informieren.
Die Teilnehmer können den Stand #26 besuchen, um mehr über die Co-Dx PCR-Testplattform und die Co-Dx Logix Smart® Suite von klinischen Laborlösungen, einschließlich Forschungsanwendungen (RUO) für das mpox-Virus, zu erfahren. Der mpox-Test des Unternehmens wurde in einer im Dezember 2023 veröffentlichten Studie in der Oxford Academic Zeitschrift Open Forum Infectious Diseases vorgestellt.
- None.
- None.
Cambridge Healthtech Institute's Next Generation Dx Summit is described as the nexus for international thought leaders to discuss diagnostic advancement and technology innovation, and offers a valuable window into how point-of-care, decentralized testing, infectious disease, liquid biopsy and companion diagnostics are changing the standard of care.
On Monday, August 19, at 12:15 PM ET, Company CEO Dwight Egan will be presenting on the Company's forthcoming PCR platform, which is currently under FDA review and is not currently for sale, in a luncheon presentation titled "Co-Dx PCR Platform: The Future of Accessible Diagnostics."
Attendees are invited to visit the Company at Booth #26 to learn more about the upcoming Co-Dx PCR testing platform as well as the Co-Dx Logix Smart® suite of clinical laboratory solutions. These solutions include Research Use Only (RUO) tests for mpox** virus, one of which was included in a study published in the Oxford Academic journal Open Forum Infectious Diseases in December, 2023. Yesterday, the World Health Organization Director-General declared mpox a public health emergency of international concern (PHEIC).
To learn more about the summit, including in-person and virtual registration details, please visit https://www.nextgenerationdx.com.
*The Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not available for sale. The Co-Dx PCR Pro instrument and Co-Dx COVID-19 Test are currently under review by the FDA and are not available for sale.
**The Co-Dx Logix Smart® Mpox and Co-Dx Logix Smart® Mpox 2-Gene tests are for Research Use Only. Not for use in diagnostic procedures.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-present-at-16th-next-generation-dx-summit-in-washington-dc-302223138.html
SOURCE Co-Diagnostics
FAQ
When and where is Co-Diagnostics (CODX) presenting at the Next Generation Dx Summit?
What will Co-Diagnostics (CODX) showcase at the Next Generation Dx Summit?
Where can attendees find Co-Diagnostics (CODX) at the Next Generation Dx Summit?
What is the title of Co-Diagnostics (CODX) CEO's presentation at the summit?
Has Co-Diagnostics (CODX) conducted any research on mpox virus tests?
